为患有痴呆症的人开处方:路线图
Ariel R Green1, Cynthia M Boyd2, Rosalphie Quiles2
1Division of Geriatric Medicine and Gerontology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. ariel@jhmi.edu.
Drugs & aging
|August 26, 2025
概括
对于痴呆症患者来说,不必要的药物处方至关重要,以减少伤害. 这份指南提供了安全戒药的路线图, 改善PWD及其伴侣的护理.
科学领域:
- 老年病学
- 药理学
- 神经学
背景情况:
- 痴呆症患者经常使用多种药物和可能不合适的药物 (PIM),增加风险.
- 药物风险可能超过益处或与PWD治疗目标不一致.
- 适当的缓解处方对于高质量的痴呆症护理至关重要,防止伤害并提高患者和护理伙伴的福祉.
研究的目的:
- 审查PWD中多药物的风险.
- 检查该群体的安全性和有效性的证据.
- 为残疾人提供实用路线图,解决与痴呆相关的独特挑战.
主要方法:
- 审查现有的老年人抑郁症处方框架.
- 调整框架以解决痴呆症特定问题,如疾病变异性和行为症状.
- 制定一个逐步的路线图,
- 包括患者和护理合作伙伴的沟通策略.
主要成果:
- 多药对痴呆症患者有很大的风险.
- 如果有系统地实施, 抑郁症可以在PWD中安全有效.
- 建议采用结构化的描述方法,包括目标提取,逐渐缩小计划和后续行动.
- 调整沟通策略以促进共同决策.
结论:
- 处方是高质量的痴呆治疗的重要组成部分.
- 拟议的路线图提供了一个结构化的方法来治疗残疾人.
- 与患者和护理合作伙伴的有效沟通是成功减产的关键.
- 这种方法旨在改善残疾人的健康状况,并减少造成的毒性损害.
相关概念视频
Drug Dosing: Geriatric Patients
104
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
104
Pharmacodynamics in Geriatric Patients: Effects of Age
99
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
99
Alzheimer's Disease: Treatment
586
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
586
Dementia
291
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
291
Drug Therapy
154
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
154
Alzheimer's Disease: Overview
1.1K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.1K


